In the long human struggle to understand why the body turns against itself, researchers in the United Kingdom are now asking whether a single molecule might address two of modern medicine's most entangled burdens at once. Beginning this September, a £2.7 million clinical trial will test whether semaglutide — a drug that mimics the body's own appetite-regulating hormone — can simultaneously reduce alcohol cravings and repair liver damage in patients caught between obesity and alcohol dependence. The CURB trial, spanning three institutions and hundreds of participants across England, Wales, and
UK launches major trial testing semaglutide for alcohol addiction and obesity
Alcohol use disorder and obesity-related liver disease cause significant morbidity and mortality, affecting tens of thousands of patients and their families across the UK.